0001493152-23-031972.txt : 20230907 0001493152-23-031972.hdr.sgml : 20230907 20230907160525 ACCESSION NUMBER: 0001493152-23-031972 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230907 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230907 DATE AS OF CHANGE: 20230907 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELITE PHARMACEUTICALS INC /NV/ CENTRAL INDEX KEY: 0001053369 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223542636 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15697 FILM NUMBER: 231242272 BUSINESS ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 BUSINESS PHONE: 2017502646 MAIL ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 FORMER COMPANY: FORMER CONFORMED NAME: ELITE PHARMACEUTICALS INC /DE/ DATE OF NAME CHANGE: 19980121 8-K 1 form8-k.htm
0001053369 false 0001053369 2023-09-07 2023-09-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

September 7, 2023

Date of Report (Date of earliest event reported)

 

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-15697   22-3542636
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

 

(201) 750-2646

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ELTP   OTCQB

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement Item

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 5, 2023 (the “Effective Date”), Carter J. Ward was appointed as the Company’s chief financial officer, secretary, and treasurer.

 

Mr. Ward previously served as the Company’s chief financial officer, with an initial tenure from July 2009 through May 2021.

 

From September 2022 to July 2023, Mr. Ward served as chief financial officer of Mirror Biologics, Inc., a privately held life science company. From May 2021 to July 2022, Mr. Ward served as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotechnology company. Prior to Mr. Ward’s initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. From September 2004 to June 2005, Mr. Ward was a consultant with Centennial Communications Corp., a Nasdaq-listed wireless communications provider, mainly engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG. Mr. Ward holds a B.S. in Accounting from Long Island University, Brooklyn, NY, from where he graduated summa cum laude.

 

In connection with Mr. Ward’s appointment as chief financial officer, Mr. Ward entered into an employment agreement with the Company on September 4, 2023 (the “Ward Employment Agreement”), effective as of September 5, 2023 pursuant to which Mr. Ward will receive a base salary of $275,000 (“Base Salary”), a guaranteed annual bonus equal to 20% of Base Salary and is eligible to receive additional performance bonuses of up to 30% of Base Salary, as determined from time-to-time by the Company’s board of directors. Additionally, Mr. Ward will receive options to purchase 3,000,000 shares of the Company’s Common Stock at a price equal to the closing price of the Company’s Common Stock on the Effective Date.

 

The Ward Employment Agreement will remain in effect until terminated by either party unless the Company or Mr. Ward delivers advance written notice of termination to the other party at least 60 days prior. In addition, the Ward Employment Agreement is subject to early termination by him or the Company in accordance with the terms of the Ward Employment Agreement.

 

Pursuant to the Ward Agreement, if Mr. Ward’s employment is terminated by the Company without cause or by Mr. Ward for good reason, then the Company must pay Mr. Ward, in addition to any then-accrued and unpaid obligations owed to him, severance payments equal to two months of his then-current base salary for each year of service, up to a maximum of 12 months.

 

The Ward Employment Agreement also contains covenants restricting Mr. Ward from soliciting the Company’s employees or customers for a period of 12 months after the termination of Mr. Ward’s employment with the Company and prohibiting him from disclosure of confidential information regarding the Company at any time.

 

The foregoing summary description of the Ward Employment Agreement is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein in its entirety by reference.

 

On September 7, 2023, the Company issued a press release announcing Mr. Ward’s appointment. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   Employment Agreement, dated September 5, 2023, between Elite Pharmaceuticals, Inc. and Carter Ward
99.1   Press Release dated September 7, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 7, 2023 ELITE PHARMACEUTICALS, INC.
   
  By: /s/ Nasrat Hakim
    Nasrat Hakim, President and CEO

 

 
EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

EXECUTION COPY

 

EMPLOYMENT AGREEMENT

 

This agreement (“Agreement”) is made on September 5, 2023, by and between Elite Pharmaceuticals, Inc., a Nevada corporation (“Company”), and Carter Ward (“Executive”).

 

WHEREAS, Company desires Executive to be the Company’s Chief Financial Officer (“CFO”) and Executive desires to provide employment services to Company in such a capacity and in accordance with the terms of this Agreement.

 

In consideration of the mutual promises and considerations herein contained, the parties hereby agree as follows:

 

A G R E E M E N T:

 

1. Employment.

 

1.1 Company hereby employs Executive in the capacity CFO reporting to the Chief Executive Officer (the “CEO”). Executive hereby accepts such employment, subject to the terms herein contained. In such capacity Executive responsibilities shall include, but is not limited to:

 

  Provide leadership for all finance and accounting and maintain positive relationships with key stakeholders/associates including auditors, counsel, Elite’s Board, and management.
  Timely and accurate closing of the books and filing of 10Qs/10Ks/8Ks, tracking cash-flows, and managing financial actions of the company including payroll, employee healthcare coverage, banking, and filing of taxes. Ensuring compliance with GAAP, SOX regulations, financial regulations, and the SEC.
  Preparing and presenting accurate budgets/forecasts to management and Elite’s Board.
  Communicating value and risk issues and corrective actions to management and Elite’s Board.
  Any other responsibilities that would be reasonable expected of the position of CFO and such responsibilities as may be assigned to you from time to time by the Company’s CEO and Elite’s Board.

 

Executive shall devote such time and effort to his Duties as are reasonably necessary for him to perform such Duties in a competent and professional manner.

 

2. Compensation and Benefits.

 

2.1. Salary. Executive’s annual base salary shall be Two Hundred and Seventy-Five Thousand Dollars ($275,000) payable in accordance with company’s payroll.

 

1

 

 

2.2. Bonus.

 

2.2.1 Annual Bonus. Executive shall be entitled to an annual bonus equal to fifty percent (50%) of Executive’s annual salary (“Annual Bonus”) based on the following criteria:

 

(a) Guaranteed Bonus. The Executive shall be entitled to twenty percent (20%) bonus payable in cash upon achieving personal KPI’s assigned by Executive and the CEO; and

 

(b) Corporate Performance Bonuses. The Executive shall be entitled to a Thirty Percent (30%) bonus payable in cash upon Company achieving its goals.

 

2.2.2 Stock Options.

 

Upon the approval by the Board of Directors of Elite, Executive shall be granted stock options to purchase (Three Million) 3,000,000 ELTP Shares. The options will vest over a three-year period, commencing one year from the date of issuance. The share price will be the stock at closing on the first day of employment.

 

2.3. Executive Benefits.

 

2.3.1. Expenses. Company shall promptly reimburse Executive for all reasonable and documented travel, and other business expenses actually and properly incurred by him in relation to Company’s business.

 

2.3.2. Company Plans. Executive shall be entitled to participate in such employee benefit plans and programs as Company may from time to time generally offer or provide to senior executive officers of Company, including medical and retirement plans. Nothing in the foregoing shall limit or restrict Company’s discretion to amend, revise or terminate any benefit or plan without notice to or consent of Executive.

 

2.3.3. Vacation. Executive shall be entitled to three (3) weeks of paid vacation per Fiscal Year, pro rated for periods of less than a full Fiscal Year.

 

3. Employment Term; Termination.

 

3.1. Employment Term. Executive’s employment hereunder shall commence on September 5, 2023 (the “Commencement Date”).

 

3.2. Events of Termination. Executive’s employment may be terminated as follows:

 

3.2.1 Termination for Cause. This Agreement may be terminated by Company for Cause. For purposes of this Agreement, “Cause” justifying the termination of this Agreement by Company is defined as: (1) failure or refusal to perform the services required hereunder; (2) a material breach by Executive of any of the terms of this Agreement; or (3) Executive’s conviction of a crime that either results in imprisonment or involves embezzlement, dishonesty, or activities injurious to Company or its reputation. Following termination pursuant to this subsection, Company’s only obligation to Executive shall be to pay to Executive all accrued Annual Salary and all accrued vacation time and any reasonable and necessary business expenses incurred by Executive in connection with his duties, all to the Date of Termination and payable in a lump sum, less applicable deductions and withholdings, as soon as administratively practicable following Executive’s termination. Notwithstanding the foregoing, any expense reimbursement will take place no later than the time required under Section 409A.

 

2

 

 

3.2.5 Without Cause. This Agreement may be terminated by Company without Cause.

 

(i) Company shall pay Executive severance payments in an amount equal to two (2) months’ Salary, for every full year of service, payable at the rate in effect upon the Date of Termination, less applicable deductions and withholdings, as soon as administratively practicable (but in no event later than 60 days) following Executive’s termination. Severance payment shall not exceed twelve (12) months. In addition, Company shall pay to Executive all accrued Salary, and any reasonable and necessary business expenses incurred by Executive in connection with his duties, all to the Date of Termination, less applicable deductions and withholdings, as soon as administratively practicable (but in no event later than 60 days) following Executive’s termination.

 

(ii) If the Company has a health insurance plan for its employees and Executive is covered under such plan, provided that Executive timely elects continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), Company shall pay, on Executive’s behalf, the portion of premiums of Executive’s group health insurance, including coverage for Executive’s eligible dependents, that Company paid immediately prior to Executive’s separation of employment with Company (“COBRA Payments”) for a period of twelve (12) months following the Date of Termination (“COBRA Period”). Company will pay such COBRA Payments for Executive’s eligible dependents only for coverage for which those dependents were enrolled immediately prior to the date of Executive’s separation of employment. Executive will continue to be required to pay that portion of the premium of Executive’s health coverage, including coverage for Executive’s eligible dependents, that Executive was required to pay as an active employee immediately prior to the date of Executive’s separation of employment. For the balance of the period that Executive is entitled to coverage under COBRA after the COBRA Period, if any, Executive shall be entitled to maintain coverage for Executive and Executive’s eligible dependents at Executive’s sole expense.

 

(iii) The Severance Payments and the COBRA Payments (if any) shall be paid so long as Executive is not in breach of any term of this Agreement, including, without limitation, Sections 4, 5, 6, 7 and 8. The Severance Payments and COBRA Payments (if any) made by Company to, or on behalf of, Executive are conditioned on the Executive signing a Severance Agreement and Release.

 

3.2.6 Resignation. This Agreement may be terminated by Executive for any reason or no reason at all by giving notice to Company of Executive’s resignation at least sixty (60) days prior to the effective resignation date. Following termination pursuant to this subsection 3.2.6, Company’s only obligation to Executive shall be to pay to Executive all accrued Salary and all accrued vacation time and any reasonable and necessary business expenses incurred by Executive in connection with his duties, all to the Date of Termination.

 

3

 

 

3.2.8 Section 409A Compliance.

 

(i) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

 

3.2.9. Termination of Employment. This Agreement shall terminate simultaneously with the termination of Executive’s employment for any reason; provided, that the covenants set forth in Sections 3, 4, 5, 6, 7 and 8 of this Agreement shall survive the termination of this Agreement to the extent provided in such Sections.

 

3.3. Definitions.

 

3.3.1. “Notice of Termination” Defined. “Notice of Termination” means a written notice that indicates the specific termination provision relied upon by Company or Executive.

 

3.3.2. “Date of Termination” Defined. “Date of Termination” means such date as Executive’s employment expires as written in the Notice of Termination.

 

4. Conflicts of Interest. As defined in the CDA.

 

5. Proprietary Information.

 

5.1 Executive represents and warrants to Company that (i) Executive is not subject to any limitation or agreement restricting employment by Company or performance of Executive’s Duties hereunder, and (ii) neither Executive nor any third party has any right or claim to Executive’s work produced on behalf of Company or using the property, personnel, or facilities of Company. Executive shall not misappropriate proprietary rights of Company or any third party.

 

5.2 Executive further agrees not to make, use, disclose to any third party, or permit to be made, used, or disclosed, any records, plans, papers, articles, notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, or other materials of any nature relating to any matter within the scope of the business of Company or concerning any of its dealings or affairs (“Materials”), whether or not developed, in whole or in part, by Executive and whether or not embodying Confidential Information (defined below), otherwise than for the benefit of Company. Executive shall not, on and after the Date of Termination, use, disclose, or permit to be used or disclosed, any such Materials, it being agreed that all such Materials shall be and remain the sole and exclusive property of Company. Immediately upon the Date of Termination, Executive shall deliver all such Materials, and all copies thereof, to Company, at its designated office.

 

4

 

 

6. Non-Competition; Non-Sollicitation; Anti-Raiding; Non-Disparagement. Without the prior written approval of the Board, Executive shall not, directly or indirectly, during his employment and until the end of one (1) year after the Date of Termination (however such termination occurs, including, without limitation, termination pursuant to Section 3.2):

 

6.1 Solicit, offer employment to, otherwise attempt to hire, or assist in the hiring of any employee or officer of Company or any of its Affiliates; (ii) encourage, induce, assist or assist others in inducing any such person to terminate his or her employment with Company or any of its Affiliates; or (iii) in any way interfere with the relationship between Company or any of its Affiliates and their employees; or

 

6.2 Make any public statement or perform or do any other act prejudicial or injurious to the reputation or goodwill of Company or any of its Affiliates or otherwise interfere with the business of Company or any of its Affiliates.

 

7. Confidentiality.

 

7.1 The term “Confidential Information” shall include, but not be limited to confidential information and the workpapers, concepts, formulas, techniques, strategies, components, programs, reports, studies, memoranda, correspondence, materials, manuals, records, data, technology, financial information, products, plans, research, service, design information, procedures, methods, documentation, policies, pricing, billing, customer lists and leads, and any other technical data, information and know-how which relates to products or customers or potential customers or suppliers or potential suppliers or are otherwise useful in the parties’ businesses, and which one of the parties considers proprietary and desires to maintain confidential. Confidential Information is entitled to protection hereunder whether or not such information is oral or written, whether or not such information is identified as such by an appropriate stamp or marking on each document provided or, if orally first provided, identified at that time as proprietary or confidential. In addition, Confidential Information shall include information developed by the Executive in the performance of his Duties under this Agreement. All such Confidential Information is extremely valuable and is intended to be kept secret to Company; is the sole and exclusive property of Company or its Affiliates; and, is subject to the restrictive covenants set forth herein. The term Confidential Information shall not include any information generally available to the public or publicly disclosed by Company (other than by the act or omission of Executive), information disclosed to Executive by a third party under no duty of confidentiality to Company or its Affiliates, information that Executive can demonstrate was in his possession prior to the date of this Agreement or Executive can demonstrate was independently developed by him without the use or assistance of Confidential Information, or information required by law or court order to be disclosed by Executive.

 

5

 

 

7.2 Executive shall not, without Company’s prior written approval, use, disclose, or reveal to any person or entity any of Company’s Confidential Information, except as required in the ordinary course of performing duties hereunder. Executive shall not use or attempt to use any Confidential Information in any manner which has the possibility of injuring or causing loss, whether directly or indirectly, to Company or any of its Affiliates.

 

7.3 In the event that Executive’s employment with Company is terminated for any reason whatsoever, he shall return to Company, promptly upon Company’s written request therefore, any documents, photographs, tapes, discs, memory devices, and other property containing Confidential Information which were received by him during his employment, without retaining copies thereof.

 

8 Assignment of Intellectual Property.

 

8.1. Executive shall promptly disclose to Company any and all Inventions (as defined below). Executive shall promptly communicate to Company all information, details and data pertaining to any Inventions in such form as Company requests. Executive agrees that Inventions, patents and patent applications are the property of Company, and any and all rights, titles or interests in and to Inventions, patents or patent applications which Executive may have in any and every jurisdiction are hereby assigned in full. Whenever Executive is requested to do so by Company, during or after the Term, Executive shall, at the Company’s sole cost and expense, promptly execute and deliver any and all applications, assignments or other documents or instruments reasonably deemed necessary or advisable by Company to apply for and obtain Letters Patent of the United States or any foreign country or to otherwise protect, confirm or establish Company’s full and exclusive interests in any Inventions. The obligations set forth in this Section 8.1 shall be binding upon the successors, assigns, executors, administrators and other legal representatives of Executive.

 

8.2 Any and all Works for Hire (as defined below) shall be considered “works made for hire” under the copyright laws of the United States or property of Company under applicable federal, state, local and foreign trademark laws (as appropriate). Executive shall promptly communicate to Company any and all Works for Hire, and any and all information, details and data pertaining to any Works for Hire, in such form as Company requests. To the extent that Works for Hire fail to qualify as (A) “works made for hire” under the copyright laws of the United States or any other jurisdiction or (B) property of Company under applicable federal, state, local or foreign trademark laws, Executive hereby assigns each Work for Hire and all right, title and interest therein in any and every jurisdiction to Company. Whenever Executive is requested to do so by Company, during or after the Term, Executive shall, at the Company’s sole cost and expense, promptly execute and deliver any and all applications, assignments or other documents or instruments reasonably deemed necessary or advisable by Company to apply for and confirm and effectuate full and exclusive ownership of Works for Hire in Company, including, but not limited to, ownership of any moral rights under the copyright law of any nation, or any other rights under the intellectual property laws of any nation. The obligations set forth in this Section 8.2 shall be binding upon the successors, assigns, executors, administrators and other legal representatives of Executive.

 

6

 

 

8.3 If a court declares that any term or provision of this Section 8 is invalid or unenforceable, the parties to this Agreement agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified.

 

8.4 Definitions.

 

8.4.1 “Inventions” Defined. “Inventions” means any and all inventions, discoveries, improvements, patent, copyrights and/or other property rights, whether or not patented or patentable made, conceived, created, developed or contributed to by Executive during the Term which are (i) directly or indirectly related to the business, operations or activities of the Company or any of its subsidiaries or affiliates, (ii) directly or indirectly related to Executive’s employment by, or performance of other services (including as a director, manager, officer, advisor, agent, representative, consultant or other independent contractor) for, the Company or any of its Affiliates, or (iii) based upon Confidential Information.

 

8.4.2 “Work for Hire” Defined. “Work for Hire” means any and all sales approaches, sales material, training material, computer software, documentation, other copyrightable works or any other intellectual property (including, but not limited to, materials or services subject to trademark or service mark registration, but excluding Inventions) made, conceived, created, developed or contributed to by Executive during the Term and which are (i) directly or indirectly related to the business, operations or activities of the Company or any of its Affiliates, (ii) directly or indirectly related to Executive’s employment by, or performance of other services (including as a director, manager, officer, advisor, agent, representative, consultant or other independent contractor) for, the Company or any of its Affiliates, or (iii) based upon Confidential Information.

 

9. Acknowledgments; Equitable Remedies. Executive acknowledges that the covenants contained in Sections 4, 5, 6, 7 and 8, including those related to duration, geographic scope, and the scope of prohibited conduct, are reasonable and necessary to protect the legitimate interests of Company. He further acknowledges that the covenants contained in Sections 4, 5, 6, 7 and 8 are designed, intended, and necessary to protect, and are reasonably related to the protection of, Company’s proprietary information, to which he will be exposed and with which he will be entrusted. Specifically, without limitation, Executive is entrusted with trade secrets regarding: Inventions, the strategic planning initiatives; business development plans; budgets; financial information; management training; future business plans; and operational strategies and procedures. Executive understands that any breach of Sections 5 or 7 will also constitute a misappropriation of Company’s proprietary rights, and may constitute a theft of Company’s trade secrets under applicable local, state, and federal statutes, and will result in a claim for injunctive relief, damages, and/or criminal sanctions and penalties against Executive by Company, and possibly others. Executive acknowledges that any breach of Sections 4, 5, 6, 7 or 8 will cause Company immediate and irreparable injury and damage, for which monetary relief would be inadequate or difficult to quantify. Company will be entitled to, in addition to all other remedies available to it, injunctive relief and specific performance to prevent a breach and to secure the enforcement of Sections 4, 5, 6, 7 or 8. Executive further acknowledges that the covenants set forth in Sections 4, 5, 6, 7 and 8 shall survive the Date of Termination in accordance with their terms

 

7

 

 

10. Miscellaneous Provisions.

 

10.1 Severability. If, in any jurisdiction, any term or provision hereof is determined to be invalid or unenforceable, (a) the remaining terms and provisions hereof shall be unimpaired; (b) any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such term or provision in any other jurisdiction; and (c) the invalid or unenforceable term or provision shall, for purposes of such jurisdiction, be deemed replaced by a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision.

 

10.2 Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the two parties hereto in separate counterparts, each of which shall be deemed to be an original and all of which taken together shall constitute one and the same agreement (and all signatures need not appear on any one counterpart), and this Agreement shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. This Agreement, once executed by a Party, may be delivered to the other Party hereto by facsimile or electronic transmission of a copy of this Agreement bearing the signature of the Party so delivering this Agreement. A faxed or electronically delivered signature shall have the same legally binding effect as an original signature.

 

10.3. Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed duly given upon receipt when delivered by hand, overnight delivery or facsimile (with confirmed delivery), or three (3) business days after posting, when delivered by registered or certified mail or private courier service, postage prepaid, return receipt requested, as follows:

 

If to Company, to:

 

Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale, New Jersey
Facsimile No.: (201) 391-7693
Attn: Chairman

 

If to Executive, to:

 

Carter Ward,
c/o Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale, NJ 07647

 

or to such other address(es) as a party hereto shall have designated by like notice to the other parties hereto.

 

8

 

 

10.4. Amendment. No provision of this Agreement may be modified, amended, waived or discharged in any manner except by a written instrument executed by both Company and Executive.

 

10.5. Entire Agreement. Except as specifically provided herein, this Agreement constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties hereto, oral or written. Company and Executive shall execute and deliver all such further documents as may be necessary to carry out the intent of the preceding sentence.

 

10.6. Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey applicable to contracts made and to be wholly performed therein.

 

10.7. Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

 

10.8. Binding Effect; Successors and Assigns. Executive may not delegate any of his duties or assign any of his rights hereunder. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, legal representatives and beneficiaries, successors and permitted assigns. Company shall require any successor (whether direct or indirect and whether by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of Company, by an agreement in form and substance reasonably satisfactory to Executive, to expressly assume and agree to perform this Agreement in the same manner and to the same extent that Company would be required to perform if no such succession had taken place.

 

10.9. Waiver. The failure of either of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Agreement or any provision hereof or the right of either of the parties hereto thereafter to enforce each and every provision of this Agreement. No waiver of any breach of any of the provisions of this Agreement shall be construed or deemed to be a waiver of any other or subsequent breach.

 

9

 

 

10.10. Capacity, etc. Each of Executive and Company hereby represents and warrants to the other that, as the case may be: (a) he or it has full power, authority and capacity to execute and deliver this Agreement and to perform his or its obligations hereunder; (b) such execution, delivery and performance shall not (and with the giving of notice or lapse of time or both would not) result in the breach of any agreements or other obligations to which he or it is a party or he or it is otherwise bound or violate any law; and (c) this Agreement is his or its valid and binding obligation enforceable in accordance with its terms.

 

10.11. Enforcement; Jurisdiction. If any party institutes legal action to enforce or interpret the terms and conditions of this Agreement, the prevailing party shall be awarded reasonable attorneys’ fees at all trial and appellate levels and the expenses and costs incurred by such prevailing party in connection therewith. Any legal action, suit or proceeding, in equity or at law, arising out of or relating to this Agreement shall be instituted exclusively in the State or Federal courts located in the State of New Jersey and each party agrees not to assert, by way of motion, as a defense or otherwise, in any such action, suit or proceeding, any claim that such party is not subject personally to the jurisdiction of any such court, that the action, suit or proceeding is brought in an inconvenient forum, that the venue of the action, suit or proceeding is improper or should be transferred, or that this Agreement or the subject matter hereof may not be enforced in or by any such court. Each party further irrevocably submits to the jurisdiction of any such court in any such action, suit or proceeding. Any and all service of process and any other notice in any such action, suit or proceeding shall be effective against any party if given personally or by registered or certified mail, return receipt requested or by any other means of mail that requires a signed receipt, postage prepaid, mailed to such party as herein provided. Nothing herein contained shall be deemed to affect or limit the right of any party to serve process in any other manner permitted by applicable law.

 

10.12. Advice of Counsel. Executive represents and warrants that he has had full opportunity to seek advice and representation by independent counsel of his own choosing in connection with the interpretation, negotiation and execution of this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

10

 

 

IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto as of the date first above written.

 

Elite Pharmaceuticals, Inc.
     
  By: /s/ Nasrat Hakim
  Name:  Nasrat Hakim
  Title: Chairman & Chief Executive Officer
     
  By: /s/ Carter Ward
  Name: Carter Ward

 

11
EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

 

Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer

 

Northvale, NJ – September 7, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023.

 

Mr. Ward previously served as the Company’s Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr. Ward join us again as CFO. Mr. Ward has over 30 years of industry experience, most recently as chief financial officer of Mirror Biologics, Inc., a privately held life science company and before that as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotech company. Prior to Mr. Ward’s initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. and was also a consultant for Centennial Communications Corp., a Nasdaq-listed wireless communications provider where he was engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG and holds a Bachelor of Science degree in accounting from Long Island University in Brooklyn, N.Y, graduating summa cum laude.

 

“I am extremely pleased to welcome Carter back,” said Nasrat Hakim, CEO and President of Elite. “Carter brings his extensive experience in this industry as well as his previous knowledge and experience with Elite. He’ll be an important asset for our management team as we grow the company through our direct sales and distribution strategy.”

 

About Elite Pharmaceuticals, Inc.

 

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

For Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations, 518-398-6222

Dianne@elitepharma.com

www.elitepharma.com

 

 

 

GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 5 eltp-20230907.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 eltp-20230907_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 eltp-20230907_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Sep. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 07, 2023
Entity File Number 001-15697
Entity Registrant Name ELITE PHARMACEUTICALS, INC
Entity Central Index Key 0001053369
Entity Tax Identification Number 22-3542636
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 165 Ludlow Avenue
Entity Address, City or Town Northvale
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07647
City Area Code (201)
Local Phone Number 750-2646
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ELTP
Entity Emerging Growth Company false
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001053369 2023-09-07 2023-09-07 iso4217:USD shares iso4217:USD shares 0001053369 false 8-K 2023-09-07 ELITE PHARMACEUTICALS, INC NV 001-15697 22-3542636 165 Ludlow Avenue Northvale NJ 07647 (201) 750-2646 false false false false false Common Stock, par value $0.001 per share ELTP EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elitepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm eltp-20230907.xsd eltp-20230907_lab.xml eltp-20230907_pre.xml ex10-1.htm ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "eltp-20230907_lab.xml" ] }, "presentationLink": { "local": [ "eltp-20230907_pre.xml" ] }, "schema": { "local": [ "eltp-20230907.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ELTP", "nsuri": "http://elitepharma.com/20230907", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-09-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://elitepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-09-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-031972-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-031972-xbrl.zip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end